Dr. Angelo Del Parigi is Pharmaceutical Executive with more than 20 years of clinical research and medical affairs experience. Currently, Executive Medical Director in Clinical Development and Medical Affairs with Boehringer-Ingelheim in Ridgefield, Connecticut, with responsibility for pipeline programs, SGLT2i/DPP4i combination, Biosimilar of Insulin glargine and Real World Evidence for Metabolism in the US organization. Previously, Senior Medical Director in Medical Affairs and Strategic Development with AstraZeneca in Wilmington, Delaware with responsibility for the medical strategy and lifecycle development planning for Dapagliflozin and the Exenatide franchise in the Diabetes Business unit. Worked with Pfizer for more than 6.5 years, in R&D and Medical Affairs leadership positions, lastly as Global Development Lead for Endocrine Diseases at the World Headquarters in New York City. Designed and led phase 1 through 4 clinical studies and formulated lifecycle management plans for drugs and medical devices. Held very visible roles, exposed to the highest corporate management levels. Interacted with regulatory authorities in the US and Europe for INDs, NDAs and CRLs. Worked as Research Fellow at the NIH – NIDDK in Phoenix (AZ) for more than 5 years, leading a pioneering program in Functional Neuroimaging for Obesity and Type 2 Diabetes. Recognized as an international expert in neuroimaging for metabolic disorders, invited speaker at international conferences and prestigious academic medical centers. Visiting Research Professor at Drexel University (Philadelphia, PA). Fellow of the Obesity Society (FTOS).

Neurophysiological underpinnings of weight gain and weight loss; Progression from overweight to obesity; Central mechanisms of hunger, taste and satiety.